|
|
|
|
|
|
Sponsors and Collaborators: |
Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00081068 |
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom's macroglobulinemia.
Condition | Intervention | Phase |
Lymphoma |
Drug: alemtuzumab |
Phase II |
Genetics Home Reference related topics: | aceruloplasminemia hemophilia |
MedlinePlus related topics: | Cancer Lymphoma |
ChemIDplus related topics: | Alemtuzumab Campath |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) |
Study Start Date: | January 2004 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients receive alemtuzumab IV over 2 hours on days 1, 3, and 5 of weeks 1-6 (course 1) in the absence of disease progression or unacceptable toxicity. Patients with a complete response undergo observation. Patients with stable disease or a minor or partial response receive an additional course of alemtuzumab, administered as in course 1, on weeks 7-12.
Patients are followed every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 13-27 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma)
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, California | |||||
Jonsson Comprehensive Cancer Center at UCLA | |||||
Los Angeles, California, United States, 90095-1781 | |||||
United States, Colorado | |||||
Rocky Mountain Cancer Centers - Denver Midtown | |||||
Denver, Colorado, United States, 80218 | |||||
United States, Illinois | |||||
Robert H. Lurie Comprehensive Cancer Center at Northwestern University | |||||
Chicago, Illinois, United States, 60611-3013 | |||||
United States, Maryland | |||||
Greenebaum Cancer Center at University of Maryland Medical Center | |||||
Baltimore, Maryland, United States, 21201 | |||||
United States, Massachusetts | |||||
Beth Israel Deaconess Medical Center | |||||
Boston, Massachusetts, United States, 02215 | |||||
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
Massachusetts General Hospital Cancer Center | |||||
Boston, Massachusetts, United States, 02114 | |||||
United States, New York | |||||
Herbert Irving Comprehensive Cancer Center at Columbia University | |||||
New York, New York, United States, 10032 | |||||
Long Island Jewish Medical Center | |||||
New Hyde Park, New York, United States, 11040 | |||||
United States, Ohio | |||||
Cleveland Clinic Taussig Cancer Center | |||||
Cleveland, Ohio, United States, 44195 | |||||
Australia, Victoria | |||||
Peter MacCallum Cancer Centre | |||||
East Melbourne, Victoria, Australia, 3002 | |||||
Canada, Ontario | |||||
McMaster Children's Hospital at Hamilton Health Sciences | |||||
Hamilton, Ontario, Canada, ON L8N 3Z5 | |||||
Princess Margaret Hospital | |||||
Toronto, Ontario, Canada, M5G 2C1 | |||||
France | |||||
Centre Hospitalier Lens | |||||
Lens, France, 62307 | |||||
United Kingdom, England | |||||
Saint Bartholomew's Hospital | |||||
London, England, United Kingdom, EC1A 7BE |
Jonsson Comprehensive Cancer Center |
National Cancer Institute (NCI) |
Study Chair: | Jennifer Gansert, MD, PhD | Jonsson Comprehensive Cancer Center |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000358811, UCLA-0309058 |
First Received: | April 7, 2004 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00081068 |
Health Authority: | United States: Federal Government |
|
|
|
|
|